Abbott making 'progress' repairing Fonterra botulism scare damage

Abbott making 'progress' repairing Fonterra botulism scare damage

Abbott Laboratories' CEO believes the company has “recovered about as well" as it could have in the year since the Fonterra WPC botulism scare that led it to recall infant formula in China, Vietnam, and Saudi Arabia.

Speaking on Abbott's Q2 conference call with analysts, Miles White, chairman and CEO, Abbott Laboratories, said the company has made progress over the last 11 months to recapture market share lost as a result of the action it was forced to take.

Illinois-based Abbott recalled batches of infant formula on the orders of the Chinese General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ) in August 2013 - days after Fonterra alerted eight customers that three lots of WPC potentially contaminated with Clostridium botulinum had entered the supply chain.

In the same week, Abbott pulled infant formula suspecting of containing the WPC in question from shelves in Vietnam and Saudi Arabia.

Abbott chief White pinpointed the scare, later revealed to have been a false alarm, as the "single biggest...setback" for the company in 2013.

"When it happens it's a year to recover because the consumer is an incredibly quality conscious consumer," he said, "once that consumer has shifted to another brand it's very difficult to regain them."

Nearly twelve months on, Abbott is feeling the effect of the Fonterra botulism scare. 

US$40m impact

In its Q2 2014 financial results, published yesterday, Abbott reported pediatric nutrition sales of US$963m (€712m) for the quarter, a 0.5% year-on-year decrease.

It has estimated the impact of the Fonterra botulism scare on its sales at US$40m (€29.5m) - an improvement on the US$75m  (€55.4m) quoted by Abbott in Q1.

"That wasn't something anybody anticipated, it wasn't something anybody wanted to happen, including Fonterra. But when it happens, it does set you back a bit," White told analysts.

"I think we've recovered about as well as we could have within that year time frame."

"I like the progress that our team is making in China and other countries."

Recapturing market share

Efforts by Abbott to recapture market share lost in the countries affected by its recalls are underway.

In Q2, Abbott launched several pediatric nutrition products, including an infant formula called Eleva in China. This is set to be followed by the Chinese launch of its new Similac QINTI infant formula, which will be manufactured at a newly constructed plant in the country.

Alongside these developments, Abbott and Fonterra recently sealed a deal that if approved will see them join forces to build a hub of up to five dairy farms in China. The project, which the companies claim will produce more than 160m liters of milk each year, came about as a direct result of the WPC incident, said White.

"You can spend your time arguing about something nobody wanted to happen, or you can look ahead and say, where are our opportunities?" White continued.

"So we constructively looked at what the companies could do together, and out of that came the notion of this dairy hub idea in China, which I think and they think will be very important for serving China," he added.

Related News

Danone slams NZ High Court for 'undue delay' in Fonterra WPC case

Danone slams NZ High Court for 'undue delay' in Fonterra WPC case

(Image: Fonterra)

Job cuts proposed at botulism scare impacted Fonterra Canpac plant

Jones Day attorney Abbott Laboratories trial

Jones Day attorney held to account following Abbott Laboratories trial

China implemented the temporary ban in the midst of the 2013 Fonterra botulism scare, which was found to be a false alarm.

China lifts 2013 ban on Fonterra infant formula ingredients

Abbott and Fonterra to join forces in widespread China expansion

Abbott and Fonterra to join forces in widespread China expansion

Fonterra issued the alert over concerns three batches of one of its whey protein concentrate products is contaminated with Clostridium Botulinum bacteria.

Fonterra issues botulism warning to whey protein concentrate customers

Danone and Nestlé facing Chinese infant formula pricing probe

Danone, Nestlé, FrieslandCampina facing Chinese infant formula pricing probe

Related Products

See more related products

Submit a comment

Your comment has been saved

Post a comment

Please note that any information that you supply is protected by our Privacy and Cookie Policy. Access to all documents and request for further information are available to all users at no costs, In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information maybe shared with the owners of that document or information.